ogivri 150 mg vial (pd for i.v. inj./inf.)
اوجيفري 150 مجم فيال (للحقن الوريدي/الوريد)
trastuzumab · 150mg
3657EGP
- Active ingredient
- trastuzumab
- Strength
- 150mg
- Form
- vial
- Manufacturer
- mylan
- Route
- injection
Uses
Used for HER2-positive breast cancer and HER2-positive metastatic gastric or gastroesophageal junction cancer.
Do not use if
No absolute contraindications are established, except severe hypersensitivity to the product.
Side effects
May cause infusion reactions, cardiomyopathy, neutropenia, fatigue, and pulmonary toxicity.
Warnings
May cause cardiomyopathy, serious infusion reactions, fetal harm, and pulmonary toxicity.
How it works
Trastuzumab is a monoclonal antibody that targets HER2 receptors and inhibits growth of HER2-overexpressing tumor cells.
Storage
Store refrigerated at 2–8°C.